Integrin-targeted nanocomplexes for tumour specific delivery and therapy by systemic administration

Biomaterials

Volumn 32, Issue 5, 2011, Pages 1370-1376

  Tagalakis, Aristides D ^a   Grosse, Stephanie M ^a   Meng, Qing Hai ^a   Mustapa, M Firouz Mohd ^b   Kwok, Albert ^a   Salehi, Shahla E ^a   Tabor, Alethea B ^b   Hailes, Helen C ^b   Hart, Stephen L ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Cancer; Gene therapy; Immunotherapy; Integrin; Nanoparticle; Neuroblastoma

Indexed keywords

BIODISTRIBUTIONS; CANCER; CANCER THERAPEUTICS; COCULTURE; CYTOTOXIC; EXPRESSION DATA; FURTHER DEVELOPMENT; IMMUNOTHERAPY; INTEGRINS; INTERLEUKIN-2; LUCIFERASE EXPRESSION; LUCIFERASE GENES; NANOCOMPLEXES; NANOPARTICLE FORMULATION; NEUROBLASTOMAS; NON-TARGETED; PLASMID DNA; SELF-ASSEMBLE; SPLENOCYTES; SYSTEMIC ADMINISTRATION; T CELLS; TUMOUR GROWTH; TUMOURS; VASCULARIZATION;

ANIMALS; CELL CULTURE; GENETIC ENGINEERING; MICROBIOLOGY; NANOPARTICLES; PEPTIDES; SEEPAGE; SOIL MECHANICS; TUMORS;

GENE THERAPY;

INTEGRIN; INTERLEUKIN 12; INTERLEUKIN 2; LUCIFERASE; NANOPARTICLE; PLASMID DNA; RECEPTOR TARGETED NANOCOMPLEX; UNCLASSIFIED DRUG;

ARTICLE; CELL INFILTRATION; COCULTURE; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOTOXIC T LYMPHOCYTE; DRUG DELIVERY SYSTEM; DRUG FORMULATION; GENE; GENETIC TRANSFECTION; LIVER CANCER; LUNG CANCER; MOUSE; NEUROBLASTOMA; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SPLEEN CANCER; SPLEEN CELL; TUMOR GROWTH; VASCULARIZATION;

ADMINISTRATION, CUTANEOUS; ANIMALS; CELL LINE, TUMOR; FEMALE; GENE THERAPY; GENE TRANSFER TECHNIQUES; INTEGRINS; INTERLEUKIN-12; INTERLEUKIN-2; MICE; NANOPARTICLES; NEOPLASMS; POLYMERASE CHAIN REACTION; TRANSFECTION;

ANIMALIA; MUS;

EID: 78649755603     PISSN: 01429612     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2010.10.037     Document Type: Article

References (26)

1. Oupicky D., Ogris M., Seymour L.W. Development of long-circulating polyelectrolyte complexes for systemic delivery of genes. J Drug Target 2002, 10:93-98.
2. Meyer M., Wagner E. pH-responsive shielding of non-viral gene vectors. Expert Opin Drug Deliv 2006, 3:563-571.
3. Grosse S.M., Tagalakis A.D., Mustapa M.F.M., Elbs M., Meng Q.-H., Mohammadi A., et al. Tumor-specific gene transfer with receptor-mediated nanocomplexes modified by polyethylene glycol shielding and endosomally cleavable lipid and peptide linkers. FASEB J 2010, 24:2301-2313.
4. Mustapa M.F.M., Grosse S.M., Kudsiova L., Elbs M., Raiber E.-A., Wong J.B., et al. Stabilized integrin-targeting ternary LPD (lipopolyplex) vectors for gene delivery designed to disassemble within the target cell. Bioconjug Chem 2009, 20:518-532.
5. Barker S.E., Grosse S.M., Siapati E.K., Kritz A., Kinnon C., Thrasher A.J., et al. Immunotherapy for neuroblastoma using syngeneic fibroblasts transfected with IL-2 and IL-12. Br J Cancer 2007, 97:210-217.
6. Siapati K.E., Barker S., Kinnon C., Michalski A., Anderson R., Brickell P., et al. Improved antitumour immunity in murine neuroblastoma using a combination of IL-2 and IL-12. Br J Cancer 2003, 88:1641-1648.
7. Trinchieri G. Interleukin-12: a cytokine at the interface of inflammation and immunity. Adv Immunol 1998, 70:83-243.
8. Cameron R.B., Spiess P.J., Rosenberg S.A. Synergistic antitumor activity of tumor-infiltrating lymphocytes, interleukin 2, and local tumor irradiation. Studies on the mechanism of action. J Exp Med 1990, 171:249-263.
9. Fearon E.R., Pardoll D.M., Itaya T., Golumbek P., Levitsky H.I., Simons J.W., et al. Interleukin-2 production by tumor cells bypasses T helper function in the generation of an antitumor response. Cell 1990, 60:397-403.
10. Gansbacher B., Zier K., Daniels B., Cronin K., Bannerji R., Gilboa E. Interleukin 2 gene transfer into tumor cells abrogates tumorigenicity and induces protective immunity. J Exp Med 1990, 172:1217-1224.
11. Mariani E., Meneghetti A., Tarozzi A., Cattini L., Facchini A. Interleukin-12 induces efficient lysis of natural killer-sensitive and natural killer-resistant human osteosarcoma cells: the synergistic effect of interleukin-2. Scand J Immunol 2000, 51:618-625.
12. Rossi A.R., Pericle F., Rashleigh S., Janiec J., Djeu J.Y. Lysis of neuroblastoma cell lines by human natural killer cells activated by interleukin-2 and interleukin-12. Blood 1994, 83:1323-1328.
13. Tanaka M., Saijo Y., Sato G., Suzuki T., Tazawa R., Satoh K., et al. Induction of antitumor immunity by combined immunogene therapy using IL-2 and IL-12 in low antigenic Lewis lung carcinoma. Cancer Gene Ther 2000, 7:1481-1490.
14. Lode H.N., Dreier T., Xiang R., Varki N.M., Kang A.S., Reisfeld R.A. Gene therapy with a single chain interleukin 12 fusion protein induces T cell-dependent protective immunity in a syngeneic model of murine neuroblastoma. Proc Natl Acad Sci U S A 1998, 95:2475-2480.
15. Yang Q., Tian Y., Liu S., Zeine R., Chlenski A., Salwen H.R., et al. Thrombospondin-1 peptide ABT-510 combined with valproic acid is an effective antiangiogenesis strategy in neuroblastoma. Cancer Res 2007, 67:1716-1724.
16. Hart S.L., Arancibia-Carcamo C.V., Wolfert M.A., Mailhos C., O'Reilly N.J., Ali R.R., et al. Lipid-mediated enhancement of transfection by a nonviral integrin- targeting vector. Hum Gene Ther 1998, 9:575-585.
17. Isberg R.R. Discrimination between intracellular uptake and surface adhesion of bacterial pathogens. Science 1991, 252:934-938.
18. Brooks P.C., Montgomery A.M., Rosenfeld M., Reisfeld R.A., Hu T., Klier G., et al. Integrin alpha v beta 3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels. Cell 1994, 79:1157-1164.
19. Gladson C.L., Hancock S., Arnold M.M., Faye-Petersen O.M., Castleberry R.P., Kelly D.R. Stage-specific expression of integrin alpha v beta3 in neuroblastic tumors. Am J Pathol 1996, 148:1423-1434.
20. Lee M., Kim S.W. Polyethylene glycol-conjugated copolymers for plasmid DNA delivery. Pharm Res 2005, 22:1-10.
21. Kaul G., Amiji M. Biodistribution and targeting potential of poly(ethylene glycol)-modified gelatin nanoparticles in subcutaneous murine tumor model. J Drug Target 2004, 12:585-591.
22. Loisel S., Le Gall C., Doucet L., Ferec C., Floch V. Contribution of plasmid DNA to hepatotoxicity after systemic administration of lipoplexes. Hum Gene Ther 2001, 12:685-696.
23. Torchilin V.P. Targeted pharmaceutical nanocarriers for cancer therapy and imaging. Aaps J 2007, 9:E128-E147.
24. Xu Y., Szoka F.C. Mechanism of DNA release from cationic liposome/DNA complexes used in cell transfection. Biochemistry 1996, 35:5616-5623.
25. Duda D.G., Sunamura M., Lozonschi L., Kodama T., Egawa S., Matsumoto G., et al. Direct in vitro evidence and in vivo analysis of the antiangiogenesis effects of interleukin 12. Cancer Res 2000, 60:1111-1116.
26. Yew N.S., Wang K.X., Przybylska M., Bagley R.G., Stedman M., Marshall J., et al. Contribution of plasmid DNA to inflammation in the lung after administration of cationic lipid:pDNA complexes. Hum Gene Ther 1999, 10:223-234.